
    
      This is a multicenter, open-label study of maralixibat in subjects diagnosed with cholestatic
      liver disease (including, but not limited to ALGS or PFIC) who have previously participated
      in a maralixibat clinical study. All subjects will receive maralixibat in this study.
    
  